Sanuwave Health (SNWV) to Release Quarterly Earnings on Thursday

Sanuwave Health (NASDAQ:SNWV) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of $0.17 per share and revenue of $13.2260 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 27, 2026 at 4:00 PM ET.

Sanuwave Health Stock Performance

Sanuwave Health stock opened at $22.19 on Tuesday. The company has a market cap of $190.39 million, a P/E ratio of -17.07 and a beta of 1.32. Sanuwave Health has a one year low of $20.84 and a one year high of $46.58. The business has a fifty day moving average of $25.65 and a two-hundred day moving average of $30.49.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Sanuwave Health in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Sanuwave Health has a consensus rating of “Moderate Buy” and an average target price of $54.00.

Hedge Funds Weigh In On Sanuwave Health

Several institutional investors and hedge funds have recently modified their holdings of the company. Opaleye Management Inc. grew its stake in Sanuwave Health by 0.8% in the 2nd quarter. Opaleye Management Inc. now owns 980,000 shares of the company’s stock worth $32,203,000 after acquiring an additional 7,998 shares during the period. Praetorian PR LLC raised its holdings in Sanuwave Health by 1,436.2% in the 4th quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock valued at $7,908,000 after acquiring an additional 247,750 shares during the last quarter. Stifel Financial Corp purchased a new position in shares of Sanuwave Health during the 4th quarter worth $5,291,000. Geode Capital Management LLC lifted its stake in shares of Sanuwave Health by 3.3% during the 4th quarter. Geode Capital Management LLC now owns 167,256 shares of the company’s stock worth $4,992,000 after purchasing an additional 5,378 shares during the period. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Sanuwave Health by 76.3% during the fourth quarter. Bridgeway Capital Management LLC now owns 39,279 shares of the company’s stock worth $1,172,000 after purchasing an additional 17,000 shares during the last quarter. Hedge funds and other institutional investors own 42.53% of the company’s stock.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.